On June 2, 2017, Bristol-Myers Squibb (BMS) and Seattle Genetics announced that they would be expanding their collaboration. The companies will be evaluating the combination of BMS s Opdivo (nivolumab) and Seattle Genetics Adcetris (brentuximab vedotin) as a potential treatment option for patieOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.